[Bone marrow cultures from patients with acute myeloid leukemia].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to B Labar.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Toxicity to the central nervous system was observed in 3 out of 15 patients receiving cyclosporin prophylaxis for graft-versus-host-disease after allogeneic bone marrow transplantation. Neurological clinical features included grand mal seizures, dysarthria and vestibular and cochlear toxicity. In all three patients, cyclosporin plasma levels were increased at the time of overt clinical neurological signs. The symptoms resolved quickly with the reduction of the cyclosporin dose.
Since 1983, twelve patients with severe aplastic anemia and nineteen patients with leukemia were treated with bone marrow transplantation. Six patients with severe aplastic anemia are still alive at 300 to 1,210 days after transplantation, and twelve patients with leukemia are alive at 199 to 671 days. The incidence of GvHD was relatively high (60%). Bacterial infections were the main causes of death.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The red cell pyruvate kinase (PK) activity, KM for phosphoenolpyruvate (PEP) and adenosine diphosphate (ADP), and thermostability properties were studied in patients with acute leukemias. The acquired PK defect was found in patients with acute myeloid leukemia, while it was normal in acute non-myeloid leukemia enzyme kinetic tests. PK abnormality was expressed in 17 patients as deficient PK activity, in 15 patients as decreased enzyme thermostability, and in 11 patients as altered PK affinity for ADP.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.